Dylan Dupuis
Stock Analyst at Roth MKM
(2.68)
# 2,046
Out of 4,711 analysts
9
Total ratings
44.44%
Success rate
33.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $1.68 | +316.67% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $2.35 | +368.09% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $5.86 | +292.49% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $42.25 | -24.26% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $0.96 | +941.88% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $1.68
Upside: +316.67%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $2.35
Upside: +368.09%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $5.86
Upside: +292.49%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $42.25
Upside: -24.26%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $0.96
Upside: +941.88%